{"id":471,"date":"2016-12-01T13:56:45","date_gmt":"2016-12-01T13:56:45","guid":{"rendered":"https:\/\/phoenixglobalgroup.com\/mi-katigoriopoiimeno\/phoenix-receives-accreditations-for-gdp-compliance-management-and-audit\/"},"modified":"2024-02-27T09:52:02","modified_gmt":"2024-02-27T09:52:02","slug":"phoenix-receives-accreditations-for-gdp-compliance-management-and-audit","status":"publish","type":"post","link":"https:\/\/phoenixglobalgroup.com\/el\/nea\/phoenix-receives-accreditations-for-gdp-compliance-management-and-audit\/","title":{"rendered":"PHOENIX receives accreditations for GDP Compliance Management and Audit"},"content":{"rendered":"
\n
\n
\n
\n

The wholesale distribution of medicinal products is under European Union regulation as an important activity in the integrated supply chain management. The quality and the integrity of medicinal products can be affected by a lack of adequate control. To this end, the European Union Commission has published guidelines on Good Distribution Practice of medicinal products for human use in the form of a\u00a0Commission guideline 2013\/C 343\/01<\/a><\/p>\n

PHOENIX already maintains a unique compliance portfolio including certifications ISO-9001:2008, ISO-14001:2004, AEO, IATA Accredited Agent and Business Ethics Code. The latest addition to this portfolio by end November 2016 is GDP Compliance Management Accreditation for Ambient and Cold Chain Temperature controlled transport of Medicinal Products and APIs, as well as for DGP Audit.
\nIt is of key importance that the quality and the integrity of the medicinal products are maintained during the entire supply chain from the manufacturer to the patient.<\/p>\n

Today’s distribution network for medicinal products is increasingly complex and involves many players. GDP guidelines lay down appropriate tools to assist wholesale distributors in conducting their activities and to prevent falsified medicines from entering the legal supply chain.
\nGuidelines introduce the following:<\/p>\n<\/div>\n